期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

脂肪性肝病的诊断与识别 被引量：2

原文传递
导出
摘要 脂肪性肝病（FLD）是一种临床概念，由多种病因引起的获得性疾病，指病变主体在肝小叶，以弥漫性肝细胞大泡性脂肪变为病理特征的临床综合征，临床上根据有无过量饮酒史，分为酒精性FLD（酒精性肝病，AFLD）和非酒精性FLD（NAFLD）。包括单纯性FLD、脂肪性肝炎、脂肪性肝硬化三种类型。半乳糖血症、糖原累积病、
作者 朱旅云
机构地区 中国人民解放军白求恩国际和平医院内分泌科
出处 《实用糖尿病杂志》 2010年第4期10-11,共2页 Journal of Practical Diabetology
关键词 脂肪性肝病 临床综合征 酒精性肝病 识别 诊断 脂肪性肝硬化 脂肪性肝炎 半乳糖血症
分类号 R575.5 [医药卫生—消化系统]
  • 相关文献

参考文献8

  • 1Hjelkrem M,Torres D,Harrison S. Nonalcoholic fatty liver disease. Minerva - Med 2008 ;99 (6) :583 - 593.
  • 2Erickson S. Nonalcoholic fatty liver disease. J - Lipid - Res 2009 ; 50Supp1:412 - 416.
  • 3Wieckowska A,Papouchado B ,Li Z,et al. Icreased hepatic and circulating interleukin -6 levels in human nonalcoholic steatohepatitis. Am - J - Gastroenterol 2008;103(6):1372-1379.
  • 4Ito S, Yukawa T, Uetake S, et al. Serum intercellular adhesion molecule - 1 in patients with nonalcoholic steatohepatitis: comparison with alcoholic hepatitis. Alcohol -Clin -Exp-Res 21307;31 :S83 -87.
  • 5Suzuki A,Angulo P,Lymp J,et al. Hyaluronic acid,an accurate serum marker for sever hepatic fibrosis in patients with non - alcoholic fatty liver disease. Liver-Int 2005 ;25(4) :799 -786.
  • 6Paleker N, Naus R, Larson S. Clincal model for distinguishing nonalcoholic steatohepatitis from simple steatosis in patients with non- alcoholic fatty liver disease. Liver - Int 2006 ;26 (2) : 151 - 156.
  • 7Angulo P, Hui J, Marchesini G, et al. The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAfld. Hepatology 2007;45(4) :846 -854.
  • 8Fatty Liver and Alcoholic Liver Disease Study Group of the Chinese Liver Disease Association..非酒精性脂肪性肝病诊疗指南[J].中华肝脏病杂志,2006,14(3):161-163. 被引量：1511

二级参考文献18

  • 1胡国平,刘凯,赵连三.多烯磷脂酰胆碱(易善复)治疗酒精性肝病和脂肪肝的系统评价[J].肝脏,2005,10(1):5-7. 被引量：108
  • 2Schwimmer JB,Behling C,Newbury R,et al.Histopathology of pediatric nonalcoholic fatty liver disease.Hepatology,2005,42:641-649.
  • 3Neuschwander Tetri BA,Caldwell SH.Nonalcoholic steatohepatitis:summary of an AASLD Single Topic Conference.Hepatology,2003,37:1202-1219.
  • 4Angulo P.Nonalcoholic fatty liver disease.N Engl J Med,2002,346:1221-1231.
  • 5Ghali P,Lindor KD.Hepatotoxicity of drugs used for treatment of obesity and its comorbidities.Semin Liver Dis,2004,24:389-397.
  • 6Harrison SA,Torgerson S,Hayashi P,et al.Vitamin E and vitamin C treatment improves fibrosis in patients with nonalcoholic steatohepatitis.Am J Gastroenterol,2003,98:2485-2490.
  • 7Angulo P.Use of ursodeoxycholic acid in patients with liver disease.Curr Gastroenterol Rep,2002,4:37-44.
  • 8Agrawal S,Bonkovsky HL.Management of nonalcoholic steatohepatitis:an analytic review.J Clin Gastroenterol,2002,35:253-261.
  • 9Comar KM,Sterling RK.Drug therapy for non-alcoholic fatty liver disease.Aliment Pharmacal Ther,2006,23:207-215.
  • 10Lok AS,McMahon B J; Practice Guidelines Committee,American Association for the Study of Liver Diseases (AASLD).Chronic hepatitis B:update of recommendations.Hepatology,2004,39:857-861.

共引文献1510

同被引文献19

  • 1逯越,于新宇,赵东利,刘超.二甲苯染毒小鼠肝和肺的形态学观察[J].中国职业医学,2006,33(3):239-239. 被引量：6
  • 2Kotronen A, Yki-Jarvinen H. Fatty liver:a novel component of the metabolic syndrome[J]. Arterioscler Thromb Vasc Biol, 2008,28(1) :27-38.
  • 3de Fronzo RA. Insulin resistance, lipotoxicity, type 2 diabetes and atherosclerosis[J]. Diabetologia, 2010,53 (7) : 1270-1287.
  • 4Czyzewska M,Wolska A, Cwiklinska A, et al. Disturbances of lipoprotein metabolism in meta-bolic syndrome [J]. Postepy Hig Med Dosw(Online), 2010,64 : 1-10.
  • 5Targher G, Bertolini L, Padovani R, et al. Non-alcoholic fatty liver disease is associated with carotid artery wall thickness in diet-controlled type 2 diabetic patients[J]. J Endocrinol Invest, 2006,29 : 55-60.
  • 6AYGUN C, KOCAMAN O, Sahin T, et al. Evaluation of metabolic syndrome frequency and carotid artery intima-media thickness as risk factors for atherosclerosis in patients with nonalcoholic fatty liver disease[J]. Dig Dis Sci, 2008,53(5 ) : 1352-1357.
  • 7FAN JG, ZHU J, LI XJ, et al. Prevalence of and risk factors for fatty liver in a general population of Shanghai , China[J].Hepatol, 2005,43 (3):508-514.
  • 8TARGHER G, ARCARO G. Non-alcoholic fatty liver disease and increased risk of cardiovascular disease [J]. Atherosclerosis, 2007, 191 (2) : 235-240.
  • 9WEISEL CP.Benzene exposure: an overview of monitoring methods and their findings[J]. Chemico-biol Interact,2010, 184(1-2) : 58-66.
  • 10FARRELL GC. Non-alcoholic steatohepatitis: what is it, and why is it important in the Asia-Pacific region? [J]. J Gastroenterol Hepatol, 2003, 18(2): 124-138.

引证文献2

二级引证文献3

实用糖尿病杂志
2010年 第4期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部